{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:17:55Z","timestamp":1768565875679,"version":"3.49.0"},"posted":{"date-parts":[[2023,3,9]]},"group-title":"Pharmacology and Therapeutics","reference-count":53,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,6,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>SGLT2 inhibitors provide multiple benefits to patients with type 2 diabetes \u2013 including improved glycemic control and decreased risks of cardiorenal disease. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Canagliflozin (300 mg) was administered to 30 healthy volunteers. Several endpoints were measured to assess clinically relevant responses \u2013 including drug-induced increases in urinary excretion of glucose, sodium, and uric acid.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    This pilot study confirmed that canagliflozin (300 mg) triggered acute changes in mean levels of several biomarkers: fasting plasma glucose (\u22124.1 mg\/dL; p=6x10), serum creatinine (+0.05 mg\/dL; p=8\u00d710\n                    <jats:sup>-4<\/jats:sup>\n                    ), and serum uric acid (\u22120.90 mg\/dL; p=5\u00d710\n                    <jats:sup>-10<\/jats:sup>\n                    ). The effects of sex on glucosuria depended upon how data were normalized. Whereas males\u2019 responses were \u223c60% greater when data were normalized to body surface area, males and females exhibited similar responses when glucosuria was expressed as grams of urinary glucose per gram-creatinine. The magnitude of glucosuria was not significantly correlated with fasting plasma glucose, estimated GFR, or age in these healthy non-diabetic individuals with estimated GFR&gt;60 mL\/min\/1.73m\n                    <jats:sup>2<\/jats:sup>\n                    .\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                    Normalizing data relative to creatinine excretion will facilitate including data from males and females in a single analysis. Furthermore, because our ongoing pharmacogenomic study (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02891954\">NCT02891954<\/jats:ext-link>\n                    ) is conducted in healthy individuals, this will facilitate detection of genetic associations with limited confounding by other factors such as age and renal function.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Registration<\/jats:title>\n                  <jats:p>\n                    NCT02462421 (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link>\n                    )\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>Research grants from the National Institute of Diabetes and Digestive and Kidney Diseases: R21DK105401, R01DK108942, T32DK098107, and P30DK072488.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2023.03.07.23286875","type":"posted-content","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T20:30:22Z","timestamp":1678393822000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-7854","authenticated-orcid":false,"given":"Simeon I.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Ren","family":"Cherng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhinous Shahidzadeh","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May E.","family":"Montasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary B.","family":"Whitlatch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-4744","authenticated-orcid":false,"given":"Braxton D.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Shuldiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Streeten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber L.","family":"Beitelshees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023061311400805000_2023.03.07.23286875v3.1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"2023061311400805000_2023.03.07.23286875v3.2","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2460"},{"key":"2023061311400805000_2023.03.07.23286875v3.3","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1367"},{"key":"2023061311400805000_2023.03.07.23286875v3.4","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14726"},{"key":"2023061311400805000_2023.03.07.23286875v3.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05402-w"},{"key":"2023061311400805000_2023.03.07.23286875v3.6","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13313"},{"key":"2023061311400805000_2023.03.07.23286875v3.7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14216"},{"key":"2023061311400805000_2023.03.07.23286875v3.8","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.506"},{"key":"2023061311400805000_2023.03.07.23286875v3.9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3632"},{"key":"2023061311400805000_2023.03.07.23286875v3.10","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1109-P"},{"key":"2023061311400805000_2023.03.07.23286875v3.11","doi-asserted-by":"crossref","unstructured":"Taylor SI , Yazdi ZS , Beitelshees AL . Pharmacological treatment of hyperglycemia in type 2 diabetes. J Clin Invest. 2021;131(2).","DOI":"10.1172\/JCI142243"},{"key":"2023061311400805000_2023.03.07.23286875v3.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1232"},{"key":"2023061311400805000_2023.03.07.23286875v3.13","doi-asserted-by":"publisher","DOI":"10.1038\/505612a"},{"key":"2023061311400805000_2023.03.07.23286875v3.14","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00246"},{"key":"2023061311400805000_2023.03.07.23286875v3.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.015"},{"key":"2023061311400805000_2023.03.07.23286875v3.16","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.5.595"},{"key":"2023061311400805000_2023.03.07.23286875v3.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19990910)86:2<156::AID-AJMG13>3.0.CO;2-5"},{"issue":"4","key":"2023061311400805000_2023.03.07.23286875v3.18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1353\/hub.2001.0045","article-title":"Towards a complete North American Anabaptist Genealogy II: analysis of inbreeding","volume":"73","year":"2001","journal-title":"Hum Biol"},{"key":"2023061311400805000_2023.03.07.23286875v3.19","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909"},{"key":"2023061311400805000_2023.03.07.23286875v3.20","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00462.2018"},{"key":"2023061311400805000_2023.03.07.23286875v3.21","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11480821"},{"key":"2023061311400805000_2023.03.07.23286875v3.22","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.251"},{"key":"2023061311400805000_2023.03.07.23286875v3.23","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12418"},{"key":"2023061311400805000_2023.03.07.23286875v3.24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13981"},{"issue":"4","key":"2023061311400805000_2023.03.07.23286875v3.25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/psp4.12498","article-title":"Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling","volume":"9","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2023061311400805000_2023.03.07.23286875v3.26","doi-asserted-by":"crossref","unstructured":"Blau JE , Bauman V , Conway EM , et al. Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight. 2018;3(8).","DOI":"10.1172\/jci.insight.99123"},{"key":"2023061311400805000_2023.03.07.23286875v3.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-018-0028-0"},{"issue":"12","key":"2023061311400805000_2023.03.07.23286875v3.28","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1016\/S0021-9258(17)39644-8","article-title":"Phosphocreatinine, a high-energy phosphate in muscle, spontaneously forms phosphocreatine and creatinine under physiological conditions","volume":"260","year":"1985","journal-title":"J Biol Chem"},{"key":"2023061311400805000_2023.03.07.23286875v3.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010241"},{"key":"2023061311400805000_2023.03.07.23286875v3.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.016"},{"key":"2023061311400805000_2023.03.07.23286875v3.31","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00134.2012"},{"key":"2023061311400805000_2023.03.07.23286875v3.32","doi-asserted-by":"publisher","DOI":"10.1038\/509282a"},{"key":"2023061311400805000_2023.03.07.23286875v3.33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.13995"},{"key":"2023061311400805000_2023.03.07.23286875v3.34","doi-asserted-by":"crossref","unstructured":"Woitowich NC , Beery A , Woodruff T . A 10-year follow-up study of sex inclusion in the biological sciences. Elife. 2020;9.","DOI":"10.7554\/eLife.56344"},{"issue":"4","key":"2023061311400805000_2023.03.07.23286875v3.35","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.xcrm.2022.100550","article-title":"Why \u201csex as a biological variable\u201d conflicts with precision medicine initiatives","volume":"3","year":"2022","journal-title":"Cell Rep Med"},{"key":"2023061311400805000_2023.03.07.23286875v3.36","unstructured":"FDA. Advisory Committee Meeting for Dapagliflozin (July 19, 2011). 2011. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM264312.pdf (downloaded, June 11, 2023)"},{"key":"2023061311400805000_2023.03.07.23286875v3.37","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0355"},{"key":"2023061311400805000_2023.03.07.23286875v3.38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010241"},{"key":"2023061311400805000_2023.03.07.23286875v3.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2004.10.016"},{"key":"2023061311400805000_2023.03.07.23286875v3.40","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00134.2012"},{"key":"2023061311400805000_2023.03.07.23286875v3.41","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1109-P"},{"key":"2023061311400805000_2023.03.07.23286875v3.42","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0002772021"},{"key":"2023061311400805000_2023.03.07.23286875v3.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0030194"},{"key":"2023061311400805000_2023.03.07.23286875v3.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.23752"},{"key":"2023061311400805000_2023.03.07.23286875v3.45","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014111067"},{"key":"2023061311400805000_2023.03.07.23286875v3.46","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909"},{"key":"2023061311400805000_2023.03.07.23286875v3.47","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00462.2018"},{"key":"2023061311400805000_2023.03.07.23286875v3.48","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.49.29365"},{"key":"2023061311400805000_2023.03.07.23286875v3.49","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(200011)185:2&lt;244::AID-JCP9&gt;3.0.CO;2-C"},{"key":"2023061311400805000_2023.03.07.23286875v3.50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1733027100"},{"key":"2023061311400805000_2023.03.07.23286875v3.51","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00079.2006"},{"key":"2023061311400805000_2023.03.07.23286875v3.52","doi-asserted-by":"publisher","DOI":"10.1113\/EP086042"},{"key":"2023061311400805000_2023.03.07.23286875v3.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.06.033"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.03.07.23286875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:29:32Z","timestamp":1768505372000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.03.07.23286875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":53,"URL":"https:\/\/doi.org\/10.1101\/2023.03.07.23286875","relation":{},"subject":[],"published":{"date-parts":[[2023,3,9]]},"subtype":"preprint"}}